Strategies to overcome resistance involve combining ICIs with natural compounds, such as silibinin, to enhance immunogenicity and targeting stromal interactions, e.g., the CCL2/CCR2 axis and decreased tumor-associated macrophage (TAM) recruitment [22,32]. The gene discussed is CCL2; the disease is neoplasm.